Categories AlphaGraphs, Earnings, Health Care

A visual representation of Johnson & Johnson (JNJ) Q1 2020 earnings results

Johnson & Johnson (JNJ) Q1 2020 earnings

Johnson & Johnson (NYSE: JNJ) reported that its first-quarter 2020 earnings and revenue came in above the analysts’ expectations citing product sales as well as lower costs and expenses. Region-wise, sales were better in the US than international. The Consumer and Pharmaceutical segments experienced solid high-single-digit growths despite declines in the Medical Devices segment.

The company is mobilizing its resources in the fight against the COVID-19 pandemic. The impact of COVID-19 has been included in the guidance. The reported sales outlook for fiscal 2020 was lowered to $77.5-80.5 billion from $85.4-86.2 billion. Adjusted earnings guidance was reduced to $7.50-7.90 from $8.95-9.10.

Past Performance

Most Popular

Should investors worry about Micron’s (MU) weak Q4 results and guidance?

The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,

What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?

Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a

NKE Earnings: Highlights of Nike’s Q1 2023 results

Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top